Medtronic (NYSE: MDT) is a global medical technology company. It develops and manufactures a wide range of devices and therapies. These products help treat chronic diseases, including heart conditions and diabetes, positioning Medtronic as a key player in the healthcare sector.
On June 3, 2026, Medtronic reported quarterly earnings of $1.55 per share, which narrowly beat the analyst consensus estimate of $1.54. As highlighted by Zacks, this figure is a decrease from the $1.62 per share reported in the same quarter of the previous year.
The company also announced strong quarterly revenue of $9.81 billion, surpassing the consensus estimate of $9.61 billion. As noted by The Wall Street Journal, the higher profit and sales are attributed to strategic steps taken by Medtronic to improve its business performance.
From a valuation standpoint, Medtronic has a price-to-earnings (P/E) ratio of approximately 20.49. This metric shows what investors are willing to pay for each dollar of earnings. The company also has a price-to-sales ratio of 2.67, comparing its stock price to its revenues.
Examining its financial health, Medtronic maintains a debt-to-equity ratio of 0.57. This ratio measures a company's debt relative to the value owned by shareholders. Its liquidity appears strong with a current ratio of 2.54, indicating a solid ability to meet short-term financial obligations.
